황반변성 치료제 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)
Macular Degeneration Treatment Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
Persistence Market Research의 황반변성 치료 시장 조사 보고서는 2024년부터 2032년까지 시장 역학, 성장 요인, 과제 및 새로운 동향에 대한 종합적인 분석을 제공합니다. 황반변성 치료제 시장의 현황과 미래 전망에 대한 통찰력을 제공합니다.
세계 황반변성 치료제 시장은 2024년 100억 달러에서 연평균 7.4%의 연평균 복합 성장률(CAGR)(연평균 성장률)로 성장하여 2032년에는 188억 달러에 달할 것으로 예상됩니다.
주요 인사이트
- 추정 시장 규모(2024년) : 100억 달러
- 2032년 예측 시장 규모(188억 달러) : 188억 달러
- 세계 시장 성장률(2024-2032년 CAGR) : 7.4%.
황반변성 치료제 시장 - 보고서 범위 :
황반변성은 중심시력에 영향을 미치는 만성 안질환으로, 노년층 시력저하의 주요 원인으로 꼽힙니다. 이 보고서는 고령화, 생활습관 변화, 진단 및 치료 기술의 발전 등 황반변성 치료 수요를 뒷받침하는 주요 요인에 대해 설명합니다.
시장 성장의 촉진요인:
시장 성장은 몇 가지 요인에 의해 촉진될 것입니다. 첫째, 고령화, 좌식 생활습관, 흡연, 유전적 소인과 같은 요인으로 인해 전 세계적으로 황반변성(AMD)의 유병률이 증가함에 따라 항혈관내피세포성장인자(항VEGF) 약물, 광역학 치료(PDT), 망막 이식 등 황반변성 치료 옵션에 대한 수요가 증가하고 있습니다. 촉진하고 있습니다. 또한, 빛간섭단층촬영(OCT), 안저자발형광(FAF) 등 영상진단 기술의 발전으로 AMD 환자의 조기 발견, 정확한 진단, 맞춤형 치료 계획이 가능해져 치료 성과와 시력 유지가 향상되고 있습니다. 또한, 새로운 약물 전달 시스템, 유전자 치료, 재생의학 접근법에 초점을 맞춘 R&D 이니셔티브는 습성 AMD, 건성 AMD, 지리적 위축을 포함한 다양한 황반변성 아형을 표적으로 하는 혁신적인 치료법을 위한 유망한 길을 제공합니다.
시장 성장 억제요인 :
전망은 밝지만, 황반변성 치료 시장은 일정한 문제에 직면해 있습니다. 높은 치료비, 제한된 보험 적용 범위, 상환 제한 등의 요인은 특히 신흥 시장과 소외계층의 황반변성 치료에 대한 환자 접근성에 영향을 미쳐 시장의 역동성과 보급률에 영향을 미칠 수 있습니다. 또한 유리체강 내 주사나 레이저 광응고술과 같은 침습적 시술과 관련된 안전성 우려, 부작용, 치료 합병증은 황반변성 치료에 대한 환자들의 순응도와 수용성을 저해해 시장 성장과 보급에 어려움을 초래할 수 있습니다. 또한, 규제 장벽, 임상시험 요건, 지적재산권 문제는 새로운 황반변성 치료제 시장 진입과 제품화를 지연시키고 업계의 혁신과 투자를 저해할 수 있습니다.
시장 기회 :
황반변성 치료제 시장은 기술 혁신과 시장 확대의 큰 기회를 가지고 있습니다. 의료 서비스 제공업체와 제약사는 황반변성 발병에 관여하는 새로운 경로, 분자 표적 및 질병 메커니즘을 표적으로 하는 차세대 치료법 개발에 집중할 수 있습니다. 예를 들어, 유전자 편집, 줄기세포 치료, 신경 보호제와 같은 새로운 치료법은 황반변성 질환의 질병 변형, 시력 회복 및 장기적인 관리에 유망한 치료법입니다. 또한 전략적 파트너십, 공동 연구 및 기술이전 계약은 황반변성 연구개발 생태계에서 지식 교환, 자원 공유 및 역량 강화를 촉진하여 혁신 속도와 과학적 발견을 임상 적용으로 전환하는 속도를 가속화할 수 있습니다. 또한 환자 교육, 옹호 활동 및 지역사회 아웃리치 프로그램에 대한 투자는 황반변성 진단, 치료 및 지원 서비스에 대한 인식을 높이고 편견을 없애고 접근성을 개선하여 환자들이 정보에 입각한 의사결정을 내리고 안과 치료에 적극적으로 참여할 수 있도록 돕습니다. 할 수 있도록 돕고 있습니다.
본 보고서에서 다룬 주요 질문들
- 2024년부터 2032년까지 황반변성 치료제 시장의 예상 CAGR은?
- 황반변성 치료 시장의 성장을 가속하는 주요 요인은?
- 황반변성 치료 시장에서 가장 큰 시장 점유율을 차지하는 치료 방식은 무엇인가?
- 황반변성 치료제 세계 시장의 주요 기업은?
- 주요 기업들이 황반변성 치료 시장에서 경쟁을 유지하기 위해 어떤 전략을 채택하고 있는가?
목차
제1장 주요 요약
제2장 시장 개요
- 시장 범위/분류
- 시장의 정의/범위/제한
- 포함 및 제외
제3장 주요 시장 동향
- 시장에 영향을 미치는 주요 동향
- 제품 개발과 혁신 동향
제4장 중요 성공 요인
- 제품 채택/사용 상황 분석
- 최근 제품 발매와 승인
- 전략적 프로모션 전략
- 질병 역학
- 규제와 상환 시나리오
- 제품 파이프라인 평가
- Porter's Five Forces 분석
- PESTLE 분석
제5장 시장 배경
- 거시경제 요인
- 예측 요인 - 관련성과 영향
- 시장 역학
제6장 COVID-19 위기 - 영향 평가
- COVID-19와 영향 분석
- 의약품별 매출
- 투여 경로별 매출
- 적응증별 매출
- 최종사용자별 매출
- 국가별 매출
- 2023년 시장 시나리오
제7장 세계의 황반변성 치료 시장 수요(금액 및 규모) 분석
- 과거 시장 매출(금액) 분석, 2019-2023년
- 현재 및 향후 시장 매출(금액) 예측, 2024-2032년
제8장 세계의 황반변성 치료 시장 분석, 약제별
- 서론/주요 조사 결과
- 과거 시장 분석(금액),2019-2023년
- 현재 및 향후 시장 예측(금액), 2024-2032년
- 의약품별 시장의 매력 분석
제9장 투여 경로별 세계황반변성 치료 시장 분석
- 서론/주요 조사 결과
- 과거 시장 분석(금액),2019-2023년
- 현재 및 향후 시장 예측(금액), 2024-2032년
- 투여 경로별 시장의 매력 분석
제10장 황반변성 치료 세계 시장 분석, 적응증별
- 서론/주요 조사 결과
- 과거 시장 분석(금액),2019-2023년
- 현재 및 향후 시장 예측(금액), 2024-2032년
- 적응증별 시장의 매력 분석
제11장 세계의 황반변성 치료 시장 분석, 최종사용자별
- 서론/주요 조사 결과
- 과거 시장 분석(금액),2019-2023년
- 현재 및 향후 시장 예측(금액), 2024-2032년
- 최종사용자별 시장의 매력 분석
제12장 세계황반변성 치료 시장 분석, 지역별
- 서론
- 과거 시장 분석(금액),2019-2023년
- 현재 및 향후 시장 예측(금액), 2024-2032년
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카(MEA)
- 지역별 시장의 매력 분석
제13장 북미의 황반변성 치료 시장 분석
제14장 라틴아메리카의 황반변성 치료 시장 분석
제15장 유럽의 황반변성 치료 시장 분석
제16장 남아시아의 황반변성 치료 시장 분석
제17장 동아시아의 황반변성 치료 시장 분석
제18장 오세아니아 황반변성 치료 시장
제19장 중동 및 아프리카(MEA)의 황반변성 치료 시장 분석
제20장 시장 구조 분석
- 기업 Tier별 시장 분석
- 주요 기업의 시장 점유율 분석(%)
- 시장 입지 분석
제21장 경쟁 분석
- 경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 상세(잠정 리스트)
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bayer AG
- Pfizer Inc.
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals Inc.
- Amgen Inc.
- Biogen
- Samsung Bioepis
- Santen Pharmaceutical Co., Ltd.
제22장 사용된 전제조건과 두자어
제23장 조사 방법
LSH
The Macular Degeneration Treatment Market report by Persistence Market Research offers a comprehensive analysis of market dynamics, growth factors, challenges, and emerging trends from the period 2024 to 2032. It provides insights into the current state and future outlook of the Macular Degeneration Treatment Market.
The global macular degeneration treatment market is projected to grow at a compound annual growth rate (CAGR) of 7.4% from USD 10 billion in 2024 to USD 18.8 billion by 2032.
Key Insights:
- Estimated Market Size (2024): USD 10 Billion
- Projected Market Size (2032): USD 18.8 Billion
- Global Market Growth Rate (CAGR 2024 to 2032): 7.4%
Macular Degeneration Treatment Market - Report Scope:
Macular degeneration is a chronic eye disorder affecting the central vision and is a leading cause of vision loss among older adults. The report outlines key drivers behind the demand for macular degeneration treatment, including the aging population, lifestyle changes, and advancements in diagnostic and therapeutic technologies.
Market Growth Drivers:
The market's growth is propelled by several factors. Firstly, the increasing prevalence of age-related macular degeneration (AMD) worldwide, driven by factors such as aging population, sedentary lifestyles, smoking, and genetic predisposition, fuels demand for macular degeneration treatment options such as anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), and retinal implants. Additionally, advancements in diagnostic imaging techniques such as optical coherence tomography (OCT) and fundus autofluorescence (FAF) enable early detection, accurate diagnosis, and personalized treatment planning for patients with AMD, enhancing treatment outcomes and vision preservation. Moreover, research and development initiatives focusing on novel drug delivery systems, gene therapies, and regenerative medicine approaches offer promising avenues for innovative treatments targeting various subtypes of macular degeneration, including wet AMD, dry AMD, and geographic atrophy.
Market Restraints:
Despite the positive outlook, the Macular Degeneration Treatment Market faces certain challenges. Factors such as high treatment costs, limited insurance coverage, and reimbursement constraints may impact patient access to macular degeneration treatments, particularly in emerging markets and underserved populations, influencing market dynamics and adoption rates. Moreover, safety concerns, adverse effects, and treatment complications associated with invasive procedures such as intravitreal injections and laser photocoagulation may deter patient compliance and acceptance of macular degeneration therapies, posing challenges to market growth and penetration. Additionally, regulatory hurdles, clinical trial requirements, and intellectual property issues may delay market entry and product commercialization for novel macular degeneration treatments, hampering innovation and investment in the industry.
Market Opportunities:
The Macular Degeneration Treatment Market offers significant opportunities for innovation and market expansion. Healthcare providers and pharmaceutical companies can focus on developing next-generation therapies targeting novel pathways, molecular targets, and disease mechanisms implicated in macular degeneration pathogenesis. For instance, emerging treatment modalities such as gene editing, stem cell therapy, and neuroprotective agents hold promise for disease modification, vision restoration, and long-term management of macular degeneration. Moreover, strategic partnerships, collaborations, and technology transfer agreements facilitate knowledge exchange, resource sharing, and capacity building in the macular degeneration research and development ecosystem, accelerating the pace of innovation and translation of scientific discoveries into clinical applications. Furthermore, investments in patient education, advocacy initiatives, and community outreach programs raise awareness, reduce stigma, and improve access to macular degeneration diagnosis, treatment, and support services, empowering patients to make informed decisions and actively participate in their eye care journey.
Key Questions Addressed in the Report:
- What is the Expected CAGR of the Macular Degeneration Treatment Market from 2024 to 2032?
- What are the Key Factors Driving the Growth of the Macular Degeneration Treatment Market?
- Which Treatment Modality Holds the Largest Market Share in the Macular Degeneration Treatment Market?
- Who are the Key Players in the Global Macular Degeneration Treatment Market?
- What Strategies are Adopted by Leading Companies to Stay Competitive in the Macular Degeneration Treatment Market?
Competitive Landscape and Business Strategies:
Key players in the Macular Degeneration Treatment Market include Novartis AG, Roche Holding AG, Regeneron Pharmaceuticals, Inc., Bayer AG, and Allergan plc, among others. These companies focus on product differentiation, market expansion, and strategic collaborations to maintain a competitive edge in the market. For instance, Novartis AG offers Lucentis(R) (ranibizumab) and Beovu(R) (brolucizumab) for the treatment of wet AMD, while Roche Holding AG markets Lucentis(R) in collaboration with Novartis. Market players also invest in patient support programs, disease awareness campaigns, and digital health solutions to enhance patient engagement, adherence, and retention in macular degeneration treatment pathways.
Key Companies Profiled:
- Novartis AG
- Roche Holding AG
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Allergan plc
Macular Degeneration Treatment Market Segmentation:
By Drug:
- Anti-vascular Endothelial Growth Factors
- Others
By Indication:
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
By Route of Administration:
- Intravenous Route
- Intravitreal Route
- Others
By Distribution Channel:
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
- Others
By Region:
- North America
- Latin America
- Europe Macular
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusions and Exclusions
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Development and Innovation Trends
4. Key Success Factors
- 4.1. Product Adoption / Usage Analysis
- 4.2. Recent Product Launches and Approvals
- 4.3. Strategic Promotional Strategies
- 4.4. Disease Epidemiology
- 4.5. Regulatory and Reimbursement Scenario
- 4.6. Product Pipeline Assessment
- 4.7. Porters Analysis
- 4.8. PESTLE Analysis
5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Per Capita Healthcare Expenditure Outlook
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Alternative Treatment Market Growth
- 5.2.2. Technological Advances
- 5.2.3. Development of Novel Products
- 5.2.4. Regulatory Imposition
- 5.2.5. Product Pipeline
- 5.2.6. Per Patient Spending
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
6. COVID-19 Crisis - Impact Assessment
- 6.1. COVID-19 and Impact Analysis
- 6.1.1. Revenue By Drug
- 6.1.2. Revenue By Route of Administration
- 6.1.3. Revenue By Indication
- 6.1.4. Revenue By End User
- 6.1.5. Revenue By Country
- 6.2. 2023 Market Scenario
7. Global Macular Degeneration Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032
- 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
8. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Drug
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2019-2023
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2024-2032
- 8.3.1. Anti-vascular Endothelial Growth Factor
- 8.3.2. Other
- 8.4. Market Attractiveness Analysis By Drug
9. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
- 9.3.1. Intravenous Route
- 9.3.2. Intravitreal Route
- 9.3.3. Others
- 9.4. Market Attractiveness Analysis By Route of Administration
10. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Indication
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2019-2023
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2032
- 10.3.1. Dry Age-related Macular Degeneration
- 10.3.2. Wet Age-related Macular Degeneration
- 10.4. Market Attractiveness Analysis By Indication
11. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By End User
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
- 11.3. Current and Future Market Size (US$ Mn) and Forecast By End User, 2024-2032
- 11.3.1. Hospitals
- 11.3.2. Ophthalmology Clinics
- 11.3.3. Ambulatory Surgical Centers
- 11.3.4. Others
- 11.4. Market Attractiveness Analysis By End User
12. Global Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
- 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia
- 12.3.6. Oceania
- 12.3.7. The Middle East and Africa (MEA)
- 12.4. Market Attractiveness Analysis By Region
13. North America Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 13.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 13.3.1. By Country
- 13.3.1.1. U.S.
- 13.3.1.2. Canada
- 13.3.2. By Drug
- 13.3.3. By Route of Administration
- 13.3.4. By Indication
- 13.3.5. By End User
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug
- 13.4.3. By Route of Administration
- 13.4.4. By Indication
- 13.4.5. By End User
- 13.5. Market Trends
- 13.6. Key Market Participants - Intensity Mapping
- 13.7. Drivers and Restraints - Impact Analysis
- 13.8. Country Level Analysis & Forecast
- 13.8.1. U.S. Macular Degeneration Treatment Market Analysis
- 13.8.1.1. Introduction
- 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.1.2.1. By Drug
- 13.8.1.2.2. By Route of Administration
- 13.8.1.2.3. By Indication
- 13.8.1.2.4. By End User
- 13.8.2. Canada Macular Degeneration Treatment Market Analysis
- 13.8.2.1. Introduction
- 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.2.2.1. By Drug
- 13.8.2.2.2. By Route of Administration
- 13.8.2.2.3. By Indication
- 13.8.2.2.4. By End User
14. Latin America Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 14.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 14.3.1. By Country
- 14.3.1.1. Brazil
- 14.3.1.2. Mexico
- 14.3.1.3. Argentina
- 14.3.1.4. Rest of Latin America
- 14.3.2. By Drug
- 14.3.3. By Route of Administration
- 14.3.4. By Indication
- 14.3.5. By End User
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug
- 14.4.3. By Route of Administration
- 14.4.4. By Indication
- 14.4.5. By End User
- 14.5. Market Trends
- 14.6. Key Market Participants - Intensity Mapping
- 14.7. Drivers and Restraints - Impact Analysis
- 14.8. Country Level Analysis & Forecast
- 14.8.1. Brazil Macular Degeneration Treatment Market Analysis
- 14.8.1.1. Introduction
- 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.1.2.1. By Drug
- 14.8.1.2.2. By Route of Administration
- 14.8.1.2.3. By Indication
- 14.8.1.2.4. By End User
- 14.8.2. Mexico Macular Degeneration Treatment Market Analysis
- 14.8.2.1. Introduction
- 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.2.2.1. By Drug
- 14.8.2.2.2. By Route of Administration
- 14.8.2.2.3. By Indication
- 14.8.2.2.4. By End User
- 14.8.3. Argentina Macular Degeneration Treatment Market Analysis
- 14.8.3.1. Introduction
- 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.3.2.1. By Drug
- 14.8.3.2.2. By Route of Administration
- 14.8.3.2.3. By Indication
- 14.8.3.2.4. By End User
15. Europe Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 15.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 15.3.1. By Country
- 15.3.1.1. Germany
- 15.3.1.2. Italy
- 15.3.1.3. France
- 15.3.1.4. U.K.
- 15.3.1.5. Spain
- 15.3.1.6. BENELUX
- 15.3.1.7. Russia
- 15.3.1.8. Rest of Europe
- 15.3.2. By Drug
- 15.3.3. By Route of Administration
- 15.3.4. By Indication
- 15.3.5. By End User
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug
- 15.4.3. By Route of Administration
- 15.4.4. By Indication
- 15.4.5. By End User
- 15.5. Market Trends
- 15.6. Key Market Participants - Intensity Mapping
- 15.7. Drivers and Restraints - Impact Analysis
- 15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Macular Degeneration Treatment Market Analysis
- 15.8.1.1. Introduction
- 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.1.2.1. By Drug
- 15.8.1.2.2. By Route of Administration
- 15.8.1.2.3. By Indication
- 15.8.1.2.4. By End User
- 15.8.2. Italy Macular Degeneration Treatment Market Analysis
- 15.8.2.1. Introduction
- 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.2.2.1. By Drug
- 15.8.2.2.2. By Route of Administration
- 15.8.2.2.3. By Indication
- 15.8.2.2.4. By End User
- 15.8.3. France Macular Degeneration Treatment Market Analysis
- 15.8.3.1. Introduction
- 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.3.2.1. By Drug
- 15.8.3.2.2. By Route of Administration
- 15.8.3.2.3. By Indication
- 15.8.3.2.4. By End User
- 15.8.4. U.K. Macular Degeneration Treatment Market Analysis
- 15.8.4.1. Introduction
- 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.4.2.1. By Drug
- 15.8.4.2.2. By Route of Administration
- 15.8.4.2.3. By Indication
- 15.8.4.2.4. By End User
- 15.8.5. Spain Macular Degeneration Treatment Market Analysis
- 15.8.5.1. Introduction
- 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.5.2.1. By Drug
- 15.8.5.2.2. By Route of Administration
- 15.8.5.2.3. By Indication
- 15.8.5.2.4. By End User
- 15.8.6. BENELUX Macular Degeneration Treatment Market Analysis
- 15.8.6.1. Introduction
- 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.6.2.1. By Drug
- 15.8.6.2.2. By Route of Administration
- 15.8.6.2.3. By Indication
- 15.8.6.2.4. By End User
- 15.8.7. Russia Macular Degeneration Treatment Market Analysis
- 15.8.7.1. Introduction
- 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.7.2.1. By Drug
- 15.8.7.2.2. By Route of Administration
- 15.8.7.2.3. By Indication
- 15.8.7.2.4. By End User
16. South Asia Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 16.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 16.3.1. By Country
- 16.3.1.1. India
- 16.3.1.2. Indonesia
- 16.3.1.3. Malaysia
- 16.3.1.4. Thailand
- 16.3.1.5. Rest of South Asia
- 16.3.2. By Drug
- 16.3.3. By Route of Administration
- 16.3.4. By Indication
- 16.3.5. By End User
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug
- 16.4.3. By Route of Administration
- 16.4.4. By Indication
- 16.4.5. By End User
- 16.5. Market Trends
- 16.6. Key Market Participants - Intensity Mapping
- 16.7. Drivers and Restraints - Impact Analysis
- 16.8. Country Level Analysis & Forecast
- 16.8.1. India Macular Degeneration Treatment Market Analysis
- 16.8.1.1. Introduction
- 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.1.2.1. By Drug
- 16.8.1.2.2. By Route of Administration
- 16.8.1.2.3. By Indication
- 16.8.1.2.4. By End User
- 16.8.2. Indonesia Macular Degeneration Treatment Market Analysis
- 16.8.2.1. Introduction
- 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.2.2.1. By Drug
- 16.8.2.2.2. By Route of Administration
- 16.8.2.2.3. By Indication
- 16.8.2.2.4. By End User
- 16.8.3. Malaysia Macular Degeneration Treatment Market Analysis
- 16.8.3.1. Introduction
- 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.3.2.1. By Drug
- 16.8.3.2.2. By Route of Administration
- 16.8.3.2.3. By Indication
- 16.8.3.2.4. By End User
- 16.8.4. Thailand Macular Degeneration Treatment Market Analysis
- 16.8.4.1. Introduction
- 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.4.2.1. By Drug
- 16.8.4.2.2. By Route of Administration
- 16.8.4.2.3. By Indication
- 16.8.4.2.4. By End User
17. East Asia Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 17.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 17.3.1. By Country
- 17.3.1.1. China
- 17.3.1.2. Japan
- 17.3.1.3. South Korea
- 17.3.2. By Drug
- 17.3.3. By Route of Administration
- 17.3.4. By Indication
- 17.3.5. By End User
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug
- 17.4.3. By Route of Administration
- 17.4.4. By Indication
- 17.4.5. By End User
- 17.5. Market Trends
- 17.6. Key Market Participants - Intensity Mapping
- 17.7. Drivers and Restraints - Impact Analysis
- 17.8. Country Level Analysis & Forecast
- 17.8.1. China Macular Degeneration Treatment Market Analysis
- 17.8.1.1. Introduction
- 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.1.2.1. By Drug
- 17.8.1.2.2. By Route of Administration
- 17.8.1.2.3. By Indication
- 17.8.1.2.4. By End User
- 17.8.2. Japan Macular Degeneration Treatment Market Analysis
- 17.8.2.1. Introduction
- 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.2.2.1. By Drug
- 17.8.2.2.2. By Route of Administration
- 17.8.2.2.3. By Indication
- 17.8.2.2.4. By End User
- 17.8.3. South Korea Macular Degeneration Treatment Market Analysis
- 17.8.3.1. Introduction
- 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.3.2.1. By Drug
- 17.8.3.2.2. By Route of Administration
- 17.8.3.2.3. By Indication
- 17.8.3.2.4. By End User
18. Oceania Macular Degeneration Treatment Market 2019-2023 and Forecast 2024-2032
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 18.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 18.3.1. By Country
- 18.3.1.1. Australia
- 18.3.1.2. New Zealand
- 18.3.2. By Drug
- 18.3.3. By Route of Administration
- 18.3.4. By Indication
- 18.3.5. By End User
- 18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Drug
- 18.4.3. By Route of Administration
- 18.4.4. By Indication
- 18.4.5. By End User
- 18.5. Market Trends
- 18.6. Key Market Participants - Intensity Mapping
- 18.7. Drivers and Restraints - Impact Analysis
- 18.8. Country Level Analysis & Forecast
- 18.8.1. Australia Macular Degeneration Treatment Market Analysis
- 18.8.1.1. Introduction
- 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.1.2.1. By Drug
- 18.8.1.2.2. By Route of Administration
- 18.8.1.2.3. By Indication
- 18.8.1.2.4. By End User
- 18.8.2. New Zealand Macular Degeneration Treatment Market Analysis
- 18.8.2.1. Introduction
- 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.2.2.1. By Drug
- 18.8.2.2.2. By Route of Administration
- 18.8.2.2.3. By Indication
- 18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Macular Degeneration Treatment Market Analysis 2019-2023 and Forecast 2024-2032
- 19.1. Introduction
- 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
- 19.3. Current and Future Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 19.3.1. By Country
- 19.3.1.1. Turkey
- 19.3.1.2. GCC Countries
- 19.3.1.3. South Africa
- 19.3.1.4. North Africa
- 19.3.1.5. Rest of Middle East and Africa
- 19.3.2. By Drug
- 19.3.3. By Route of Administration
- 19.3.4. By Indication
- 19.3.5. By End User
- 19.4. Market Attractiveness Analysis
- 19.4.1. By Country
- 19.4.2. By Drug
- 19.4.3. By Route of Administration
- 19.4.4. By Indication
- 19.4.5. By End User
- 19.5. Market Trends
- 19.6. Key Market Participants - Intensity Mapping
- 19.7. Drivers and Restraints - Impact Analysis
- 19.8. Country Level Analysis & Forecast
- 19.8.1. Turkey Macular Degeneration Treatment Market Analysis
- 19.8.1.1. Introduction
- 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.1.2.1. By Drug
- 19.8.1.2.2. By Route of Administration
- 19.8.1.2.3. By Indication
- 19.8.1.2.4. By End User
- 19.8.2. GCC Countries Macular Degeneration Treatment Market Analysis
- 19.8.2.1. Introduction
- 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.2.2.1. By Drug
- 19.8.2.2.2. By Route of Administration
- 19.8.2.2.3. By Indication
- 19.8.2.2.4. By End User
- 19.8.3. South Africa Macular Degeneration Treatment Market Analysis
- 19.8.3.1. Introduction
- 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.3.2.1. By Drug
- 19.8.3.2.2. By Route of Administration
- 19.8.3.2.3. By Indication
- 19.8.3.2.4. By End User
- 19.8.4. North Africa Macular Degeneration Treatment Market Analysis
- 19.8.4.1. Introduction
- 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.4.2.1. By Drug
- 19.8.4.2.2. By Route of Administration
- 19.8.4.2.3. By Indication
- 19.8.4.2.4. By End User
20. Market Structure Analysis
- 20.1. Market Analysis by Tier of Companies
- 20.2. Market Share Analysis (%) of Top Players
- 20.3. Market Presence Analysis
- 20.3.1. By Regional footprint of Players
- 20.3.2. Product footprint by Players
- 20.3.3. Channel Foot Print by Players
21. Competition Analysis
- 21.1. Competition Dashboard
- 21.2. Competition Benchmarking
- 21.3. Competition Deep Dive (Tentative List)
- 21.3.1. F. Hoffmann-La Roche Ltd.
- 21.3.1.1. Overview
- 21.3.1.2. Product Portfolio
- 21.3.1.3. Key Financials
- 21.3.1.4. Sales Footprint
- 21.3.1.5. SWOT Analysis
- 21.3.1.6. Strategy Overview
- 21.3.2. Novartis AG
- 21.3.2.1. Overview
- 21.3.2.2. Product Portfolio
- 21.3.2.3. Key Financials
- 21.3.2.4. Sales Footprint
- 21.3.2.5. SWOT Analysis
- 21.3.2.6. Strategy Overview
- 21.3.3. Bayer AG
- 21.3.3.1. Overview
- 21.3.3.2. Product Portfolio
- 21.3.3.3. Key Financials
- 21.3.3.4. Sales Footprint
- 21.3.3.5. SWOT Analysis
- 21.3.3.6. Strategy Overview
- 21.3.4. Pfizer Inc.
- 21.3.4.1. Overview
- 21.3.4.2. Product Portfolio
- 21.3.4.3. Key Financials
- 21.3.4.4. Sales Footprint
- 21.3.4.5. SWOT Analysis
- 21.3.4.6. Strategy Overview
- 21.3.5. Bausch Health Companies Inc.
- 21.3.5.1. Overview
- 21.3.5.2. Product Portfolio
- 21.3.5.3. Key Financials
- 21.3.5.4. Sales Footprint
- 21.3.5.5. SWOT Analysis
- 21.3.5.6. Strategy Overview
- 21.3.6. Regeneron Pharmaceuticals Inc.
- 21.3.6.1. Overview
- 21.3.6.2. Product Portfolio
- 21.3.6.3. Key Financials
- 21.3.6.4. Sales Footprint
- 21.3.6.5. SWOT Analysis
- 21.3.6.6. Strategy Overview
- 21.3.7. Amgen Inc.
- 21.3.7.1. Overview
- 21.3.7.2. Product Portfolio
- 21.3.7.3. Key Financials
- 21.3.7.4. Sales Footprint
- 21.3.7.5. SWOT Analysis
- 21.3.7.6. Strategy Overview
- 21.3.8. Biogen
- 21.3.8.1. Overview
- 21.3.8.2. Product Portfolio
- 21.3.8.3. Key Financials
- 21.3.8.4. Sales Footprint
- 21.3.8.5. SWOT Analysis
- 21.3.8.6. Strategy Overview
- 21.3.9. Samsung Bioepis
- 21.3.9.1. Overview
- 21.3.9.2. Product Portfolio
- 21.3.9.3. Key Financials
- 21.3.9.4. Sales Footprint
- 21.3.9.5. SWOT Analysis
- 21.3.9.6. Strategy Overview
- 21.3.10. Santen Pharmaceutical Co., Ltd.
- 21.3.10.1. Overview
- 21.3.10.2. Product Portfolio
- 21.3.10.3. Key Financials
- 21.3.10.4. Sales Footprint
- 21.3.10.5. SWOT Analysis
- 21.3.10.6. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
